1.Advancing breast cancer and lung cancer screening: Expert perspectives to advance programmes in Singapore.
Clive TAN ; Ern Yu TAN ; Geak Poh TAN ; Ravindran KANESVARAN
Annals of the Academy of Medicine, Singapore 2025;54(8):498-504
INTRODUCTION:
The high prevalence and mortality rates of breast cancer and lung cancer in Singapore necessitate robust screening programmes to enable early detection and intervention for improved patient outcomes, yet 2024 uptake and coverage remain suboptimal. This narrative review synthesises expert perspectives from a recent roundtable discussion and proposes strategies to advance breast cancer and lung cancer screening programmes.
METHOD:
A 2024 roundtable convened clinical practitioners, health policymakers, researchers and patient advocates discussed current challenges and opportunities for improving cancer screening in Singapore. Perspectives and insights were analysed to identify themes related to existing programme gaps, opportunities for innovation and implementation challenges.
DISCUSSION:
Singapore's national breast cancer screening programme has been in place for over 2 decades, yet screening uptake remains suboptimal. A national lung cancer screening programme, in contrast, is still in its early stages of implementation. Regardless, employment of risk stratification approaches that integrate genetic, demographic and lifestyle factors could enhance screening effectiveness by identifying high-risk indivi-duals, while also taking local epidemiological trends into consideration. Integration of digital health technologies, artificial intelligence and behavioural change models can enhance cancer screening uptake and accuracy to overcome barriers such as low awareness, cultural beliefs and socioeconomic factors that contribute to low participation rates.
CONCLUSION
Key recommendations include enhancing public awareness, refining screening guidelines, expanding access and applying innovative technologies. A coordinated effort among stakeholders is crucial to continually assess and enhance screening programmes to narrow the practice-policy gap and ultimately reduce breast cancer and lung cancer burden in Singapore.
Humans
;
Singapore/epidemiology*
;
Lung Neoplasms/epidemiology*
;
Breast Neoplasms/epidemiology*
;
Early Detection of Cancer/methods*
;
Female
;
Mass Screening/organization & administration*
2.The therapeutic dilemma of idiopathic granulomatous mastitis.
Ee Ling Serene TANG ; Chi Shern Bernard HO ; Patrick Mun Yew CHAN ; Juliana Jia Chuan CHEN ; Mui Heng GOH ; Ern Yu TAN
Annals of the Academy of Medicine, Singapore 2021;50(8):598-605
INTRODUCTION:
Idiopathic granulomatous mastitis (IGM) is a rare, benign, chronic breast condition that can cause repeated abscesses or mass formation in bilateral breasts. The condition can severely impact the quality of life of affected women. This study aims to evaluate effective treatment modalities, as well as understand the demographics and clinical presentation of patients with IGM.
METHODS:
An 11-year retrospective review was performed of patients diagnosed with IGM from 1 January 2008 to 31 December 2018 at a tertiary breast unit.
RESULTS:
A total of 77 patients were included in the study. The median age at presentation was 36 years old. IGM presented most commonly as a breast lump (98.1%). The median number of flares was 2 (1-12). Of the 77 patients, 68.8% (53) were treated with antibiotics, 50.6% (39) with steroids, and 44.2% (34) underwent surgery, in the course of their IGM treatment. Forty-five (59.2%) of the 76 patients with IGM required a multimodal treatment approach to achieve remission. There was no significant difference in the number of flares no matter the initial treatment (
CONCLUSION
IGM is a clinical diagnosis. It is a rare, relapsing breast inflammatory condition that affects young females with no superior treatment modality. Smoking is associated with higher number of flares of IGM and should be discouraged in IGM patients.
Adult
;
Anti-Bacterial Agents/therapeutic use*
;
Female
;
Granulomatous Mastitis/therapy*
;
Humans
;
Quality of Life
;
Retrospective Studies
;
Treatment Outcome
3.Understanding the Psychosocial Needs of Women who Present with Advanced Breast Cancer.
Ee Ling Serene TANG ; Pei Yi SIN ; Juliana Jia Chuan CHEN ; Mun Yew Patrick CHAN ; Melanie Dee Wern SEAH ; Sarah Qinghui LU ; Mui Heng GOH ; Ern Yu TAN
Annals of the Academy of Medicine, Singapore 2020;49(12):990-995
INTRODUCTION:
Advanced breast cancer (ABC) remains common in Singapore. In 2019, 22.1% of breast cancer patients presented with ABC in our institution. Despite increasing affluence and the advent of national mammographic screening, the incidence of ABC has not changed significantly. This suggests inherent differences in women who present late. We aim to explore the socio-economic background, knowledge and attitudes of women who present with ABC.
METHODS:
Between December 2013 and July 2015, 100 patients who presented consecutively with ABC in a tertiary institution in Singapore were recruited to participate in an interviewer-led questionnaire exploring psychosocial and economic issues.
RESULTS:
Among the 100 patients, 63 and 37 presented with stages 3 and 4 breast cancer respectively. Median age was 57 (27-86), 52% had at least secondary education, 53% had no formal employment and 71% were married; 88% were aware of breast cancer symptoms, 82% were aware that mammography can help detect cancer, 82% believed that current treatment modality for breast cancer is effective, 96% had never undergone a mammography and 52.9% felt mammograms were unnecessary. A total of 64% presented symptomatic from the breast tumour, with a median duration of 3 months. Many of the patients were aware of breast cancer symptoms and the utility of mammography. However, a group of patients did not comply with screening. This may be due to poor understanding about breast screening and detection in its asymptomatic phase.
CONCLUSION
Further public education to improve understanding of breast cancer and screening mammography may help to improve rates for earlier detection of breast cancer.
4.Limiting the use of primary endocrine therapy in elderly women with breast cancer.
Shaun W Y CHAN ; Patrick M Y CHAN ; Melanie D W SEAH ; Juliana J C CHEN ; Ern Yu TAN
Annals of the Academy of Medicine, Singapore 2014;43(9):469-472
Primary endocrine therapy (PET) is often included as a treatment option in elderly women with operable breast cancer. Elderly women tend to have pre-existing comorbidities and are often reluctant to undergo surgery. The benefit of surgery needs to be weighed against a relatively higher potential for operative morbidity and mortality, and a limited life expectancy. But while PET can provide relatively good locoregional control, it is not curative in nature and the possibility of local complications and metastasis remains. We retrospectively reviewed the outcome of PET in a series of 19 elderly women, older than 70 years of age, who had presented with operable non-metastatic breast cancer. Only about a third of these women were deemed medically unfit for surgery; the rest had declined surgery. Compliance was an issue, with almost half of these patients defaulting treatment and follow-up. Local control was achieved in most patients, but disease progression did occur in 5 patients. Three of these patients received additional treatment; which included surgery in 1 patient. PET should therefore not be considered an equivalent alternative to surgery in elderly women who were fi t to undergo surgery. However, having observed that only 1 of the 6 deaths in our study was related to breast cancer, PET does have a role in women whose life expectancy is more likely to be limited by coexisting morbidities than the breast cancer itself.
Aged
;
Aged, 80 and over
;
Antineoplastic Agents, Hormonal
;
therapeutic use
;
Breast Neoplasms
;
drug therapy
;
Drug Therapy
;
utilization
;
Female
;
Humans
;
Retrospective Studies
;
Tamoxifen
;
therapeutic use
5.The use of traditional Chinese medicine among breast cancer patients: implications for the clinician.
Kar Yong WONG ; Ern Yu TAN ; Juliana J C CHEN ; Christine TEO ; Patrick M Y CHAN
Annals of the Academy of Medicine, Singapore 2014;43(2):74-78
INTRODUCTIONTraditional Chinese Medicine or Traditional Complementary Medicine (TCM) is commonly used in our culture. There are several concerns regarding its use in patients undergoing conventional treatments for breast cancer. In this study, we aimed to evaluate the prevalence and pattern of TCM use among our breast cancer patients, and to identify patients who were most likely to choose TCM.
MATERIALS AND METHODSA total of 300 patients on active follow-up with Breast Service at Tan Tock Seng Hospital were interviewed using a structured questionnaire.
RESULTSA total of 35% (104 of 296) of patients reported using TCM. The majority of the patients were introduced to TCM by family and friends following the diagnosis of breast cancer. All except 3 patients continued with recommended conventional therapy although most did not inform their clinicians of TCM use. None of the patients reported any serious adverse events and 75% of them perceived a benefit from TCM use. Younger patients and those of Chinese ethnicity were more likely to use TCM (P <0.01 and P = 0.03 respectively). There was no significant difference in the dialect group, religious beliefs and educational level between the 2 groups (P >0.05).
CONCLUSIONTCM use is common among our breast cancer patients, particularly the younger women. However, most patients do not inform their clinicians of TCM use while on recommended conventional therapies. It is therefore important for clinicians to initiate discussions regarding TCM use in order to be aware of potential unwanted drug interactions.
Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms ; therapy ; Female ; Humans ; Medical Oncology ; Medicine, Chinese Traditional ; utilization ; Middle Aged

Result Analysis
Print
Save
E-mail